JBC Advanced Glycation Endproducts

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M005447200 on August 14, 2000

J. Biol. Chem., Vol. 275, Issue 44, 34197-34204, November 3, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/44/34197    most recent
M005447200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhakat, K. K.
Right arrow Articles by Mitra, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhakat, K. K.
Right arrow Articles by Mitra, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Regulation of the Human O6-Methylguanine-DNA Methyltransferase Gene by Transcriptional Coactivators cAMP Response Element-binding Protein-binding Protein and p300*

Kishor K. Bhakat and Sankar MitraDagger

From the Sealy Center for Molecular Science and Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston, Texas 77555

Received for publication, June 21, 2000, and in revised form, August 8, 2000


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

O6-Methylguanine-DNA methyltransferase (MGMT)1, a ubiquitous DNA repair protein, removes O6-alkylguanine from DNA, including cytotoxic O6-chloroethylguanine induced by chemotherapeutic N-alkyl N-nitrosourea-type drugs, e.g. 1,3-bis(2-chloroethyl)-1-nitrosourea. Treating the pancreatic carcinoma cell line MIA PaCa-2 with trichostatin A (TSA), a specific inhibitor of histone deacetylase, increased MGMT mRNA and protein levels by 2-3-fold. Surprisingly, TSA treatment increased MGMT promoter-dependent luciferase activity by some 40-fold in a transient reporter expression assay. Deletion and point mutation analysis showed that two AP-1 binding sites in the MGMT promoter are involved in activation by TSA. Ectopic expression of the transcriptional coactivators cAMP response element-binding protein-binding protein (CBP) and p300, which have intrinsic histone acetyltransferase activity, enhanced luciferase expression. Overexpression of adenovirus E1A, which binds CBP/p300, strongly inhibited both basal and TSA-inducible MGMT promoter activity, while a mutant E1A, defective in binding CBP/p300, did not. Chromatin immunoprecipitation assays revealed that TSA treatment increased histone acetylation in the endogenous MGMT promoter region, which also showed association with CBP/p300. Taken together, our results indicate that targeted histone acetylation results in the remodeling of chromatin by recruitment of the coactivator CBP/p300, and constitutes an important step in regulating MGMT expression.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Antitumor alkylating drugs of the 2-haloethyl-N-nitrosourea class, such as 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU),1 induce O6-chloroethylguanine in DNA, which in a second reaction forms DNA cross-links, the ultimate cytotoxic lesion (1). O6-Methylguanine-DNA methyltransferase (MGMT), a ubiquitous DNA repair protein, repairs the mutagenic, carcinogenic and cytotoxic O6-alkylguanine adducts including the primary alkyl adducts induced by alkylnitrosoureas (2, 3). MGMT acts by transferring the O6-alkyl group to a specific cysteine residue within its own sequence in a single step, stoichiometric reaction (4). This transfer irreversibly inactivates MGMT. Hence, MGMT is a major contributor to cellular protection from the mutagenic, carcinogenic, and cytotoxic effects of DNA-alkylating agents. MGMT expression is highly variable in normal tissues as well as in tumor cells (5, 6). A fraction of primary tumor cells, and 20% of human tumor cell lines, lack expression of MGMT (7, 8). These MGMT-defective (Mex-) cell lines are highly sensitive to alkylating agents and nitrosourea-type drugs (8). Conversely, some tumor cells express MGMT at a high level and are highly resistant to chemotherapy with BCNU (9). Thus, elucidating the molecular mechanisms controlling MGMT expression is of major clinical significance.

The MGMT gene encoding an mRNA of 950 nucleotides consists of five exons, and spans more than 170 kilobase pairs (10, 11). The 5'-regulatory sequence (including its promoter) has been cloned (12). The promoter is extremely GC-rich, and lacks both TATA and CAAT boxes. Several cis elements were identified, including six putative Sp1 sites within the CpG island, two glucocorticoid-responsive elements (GRE), and two each of putative AP-1 and AP-2 elements (12). The potential function of each of the GRE and AP-1 sites in activation of MGMT has been investigated previously (13, 14). However, the molecular basis for the lack of expression of MGMT in Mex- cell lines, in which no deletion or gross rearrangement in the gene was observed, is not understood (15). Reporter gene expression driven by the MGMT promoter indicates that Mex- cells do not lack necessary trans-acting factors (16). This suggests that gene silencing results from modification of cis elements, by mechanisms such as CpG methylation (17) and/or chromatin alteration (18).

Recent studies have established that chromatin remodeling via histone modifying enzymes, namely histone acetyltransferase (HAT) and histone deacetylase (HDAC), is involved in transcriptional activation and repression, respectively (19, 20). It has been proposed that acetylation of the epsilon -amino group of lysine residues at the NH2-terminal domain of histones promotes destabilization of histone-DNA interaction in the nucleosome, resulting in increased accessibility of the open chromatin to the transcriptional machinery (19), while histone deacetylase reverses this process by removing the acetyl groups, and represses transcription (20). In agreement with this hypothesis, several studies demonstrated enrichment of hyperacetylated histones within the transcriptionally active/competent chromatin in vivo, and hypoacetylated histones were shown to be concentrated in transcriptionally silenced domains (19, 21).

Trichostatin A (TSA), a specific and potent inhibitor of histone deacetylase, modulates expression of only 2% of cellular genes, which implies that acetylation may be targeted to specific genes or chromosomal domains (22, 23). A simple but attractive hypothesis is that targeted histone acetylation is achieved by recruitment of acetyltransferase to the signal-responsive promoters. Strong support for this idea was provided by the recent observations that transcription cofactors, including CBP, p300, PCAF, GCN5, ACTA, SRC-1, and TAFII 250 subunits of TFIID have intrinsic HAT activity, and are recruited to the promoter region in a signal-dependent process (for review, see Ref. 24).

The transcriptional coactivators CBP and p300, originally identified as adenovirus E1A-binding proteins (25), have long been recognized as key molecules for gene regulation by communicating between transcription factors and the basal transcription machinery. CBP and p300 are functional homologues and henceforth referred to as CBP/p300 (26). CBP/p300 does not by itself interact with a specific DNA sequence; instead, it interacts with multiple transcription factors including AP-1 via dedicated domains, and form multiprotein complexes, named "enhanceosomes" (27-29). The functional requirements for the HAT activities of CBP/p300 (30) and PCAF have recently been examined, along with their roles in regulation of differentiation, transcription activation, and signaling pathways (19, 24).

By examining the contribution of chromatin remodeling to transcriptional regulation of the human MGMT gene, we show in this report that histone hyperacetylation activates MGMT gene in MIA PaCa-2 cells, and transcriptional co-activator CBP/p300 is involved in both basal and TSA-induced, AP-1-mediated MGMT promoter activation. We also discuss the possible mechanism for the remodeling of chromatin structure of the MGMT gene that is needed to regulate its expression.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture and Reagents-- MIA PaCa-2 (ATCC CRL-1420) cells were grown at 37 °C in high glucose Dulbecco's modified Eagle's medium (Life Technologies, Inc.) medium supplemented with 10% fetal bovine serum (Life Technologies, Inc.), 2.5% horse serum (Life Technologies, Inc.), 1 mM sodium pyruvate (Sigma), and penicillin (100 units/ml) and streptomycin (100 µg/ml). Trichostatin A (TSA) was purchased from Biomol (Plymouth Meeting, PA).

Northern Analysis-- After extraction of total cellular RNA with RNAzol (Tel-Test, Inc.), 50 µg of RNA/lane was electrophoresed on a 1% agarose gel, and then transferred onto Protran nitrocellulose membrane (Schleicher & Schuell) by capillary electrophoresis (31), and then hybridized with 32P-labeled MGMT cDNA or 18 S rRNA as probe. The MGMT cDNA probe was an EcoRI fragment of pKT100 (10). Both prehybridization and hybridization were carried out at 65 °C with QuickHyb hybridization solution (Stratagene), and the membrane was subsequently washed according to the manufacturer's protocol. The signal intensity was quantified by ImageQuant (Molecular Dynamics).

Immunoblot Analysis-- TSA-treated or untreated cells were lysed by incubating with lysis buffer containing 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 100 µg/ml phenylmethylsulfonyl fluoride, and protease inhibitor mixture (Roche Molecular Biochemicals) on ice for 15 min. After three cycles of freezing and thawing, the lysates were centrifuged (12,000 × g, 10 min at 4 °C), and the supernatants collected and stored at -80 °C. After protein concentration was determined with Bio-Rad reagent, SDS-PAGE (12.5% polyacrylamide) was carried out (50 µg of protein/lane). Western analysis was performed with polyclonal MGMT antibody as described previously (13). Histones were extracted from TSA-treated or untreated cultured cells and SDS-PAGE (12.5% polyacrylamide) was carried out (5 µg/lane). Polyclonal anti-acetylated histone H4 antibody (Upstate Biotechnology, Inc.) was used at 4 µg/ml.

Analysis of Histones-- The histones were extracted from the cells according to Cousens et al. (32). Different isoforms of acetylated histones from TSA treated or untreated cells were analyzed by acid-urea-Triton (AUT) slab gel electrophoresis as described by Yoshida et al. (22).

Chromatin Immunoprecipitation (CHIP) Assay-- Immunoprecipitation of chromatin with anti-acetylated histone H4 antibody was performed by a modified procedure of Braunstein et al. (21). After treatment of approximately 1 × 107 cells in the culture medium with TSA for 9 h, the treated and control cells were incubated in 1% formaldehyde at 37 °C for 10 min to allow reversible cross-linking of proteins, including histones, to DNA. The cells were harvested and lysed in 0.5 ml of lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor mixture), and sonicated 10 times for 10 s at 0 °C. After clarification of the lysate by centrifugation, 0.1 ml of supernatant containing solubilized chromatin was diluted 10-fold with dilution buffer containing 0.01% SDS, 1% Triton X-100, 1.2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH 8.0. To reduce nonspecific background, the diluted chromatin solution was shaken for 40 min at 4 °C with 60 µl of protein A-agarose slurry as 50% suspension in 10 mM Tris-HCl, pH 8.0, 1 mM EDTA (TE), which was pretreated with salmon sperm DNA.

For immunoprecipitation, the treated chromatin solution was incubated overnight at 4 °C with 5 µg of anti-acetylated histone H4 antibody. The immunocomplex was then purified by binding to 60 µl of protein A-agarose slurry as before. After incubation for 1 h at 4 °C, the agarose beads were collected by centrifugation, sequentially washed twice with dilution buffer, once with dilution buffer containing 500 mM NaCl, and once with a buffer containing 0.25% LiCl, 1% Nonidet P-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 8.1. Finally the beads were washed with TE, and the complexes eluted with two 250-µl aliquots of elution buffer (1% SDS, 0.1 M NaHCO3) at room temperature for 15 min. The pooled eluates were heated to 65 °C for 4-5 h to reverse the formaldehyde cross-links and then treated with proteinase K for 3 h. The DNA was subsequently extracted with phenol/chloroform, precipitated with ethanol, and the precipitate dissolved in 20 µl of TE. PCR amplification of DNA was carried out with diluted aliquots, using oligonucleotides 5'-GCTCCAGGGAAGAGTGTCCTCTGCTCCCT and 5'-GGCCTGTGGTGGGCGATGCCGTCCAG as 5' and 3' primers, respectively, encompassing the two AP-1 sites in the MGMT promoter region. To ensure that PCR amplification was in the linear range, the PCR products with different dilutions of input DNA were quantitated. The PCR products were separated by agarose gel electrophoresis and their sequences confirmed directly. In some experiments, cells were transfected with MGMT promoter-reporter (p-954/+24ML) and the CHIP assay was performed as before. In this case the 3' primer for PCR, 5'-GGCCTGTGGTGGGCGATGCCGTCCAG corresponded to 3' of the MGMT promoter and the 5' primer 5'-TGTATCTTATGGTACTGTAACTG to a sequence in the pGL2 basic vector. For PCR of non-coding region of the pGL2 basic vector, the 5' primer was 5'-GGTAATACGGTTATCCACAGAAT and the 3' primer was 5'-GTTACCAGTGGCTGCTGCCAGTGGC.

Transient Transfection and Plasmids-- Exponentially growing MIA PaCa-2 cells (5 × 106/dish) were suspended in 300 µl of PBS, electroporated at 960 microfarads and 220 V using a Gene Pulser (Bio-Rad), and transferred back to dishes containing culture medium. The medium was replaced with fresh medium containing TSA or ethanol, at 24 h after transfection. After TSA treatment for another 24 h, the cells were harvested and lysed with Reporter Lysis Buffer (Promega), and the luciferase activity of the extracts was measured in a luminometer using the luciferase assay kit (Promega). The luciferase activity was normalized with respect to the protein concentration of the lysate. In some experiments, 2 µg of beta -galactosidase expression plasmid pCMVbeta (CLONTECH) was included in the transfection procedure, so that beta -gal activity could be used to correct for variation in transfection efficiency.

The following plasmids were used in the transfection assays. All the deletion constructs of MGMT-luciferase (p-72/+24ML, p-575/+24ML, p-954/+24ML, and p-3500/+24ML) cloned in pGL2 basic vector (Promega) have been described previously (13). Site-directed mutation of two AP-1 sites in p-954/+24ML reporter plasmid was described by Boldogh et al. (14). pcDNA3 (Invitrogen), pGL2-control vector (Promega), and pCMVbeta (CLONTECH) were used as controls. pCMV-E1A encoding adenovirus E1A 12 S protein and mutant Delta 2-36 E1A were kind gifts of Dr. P. K. Roychoudhury (University of Illinois, Chicago, IL). pRC/RSV mCBP encoding the full-length mouse CBP was generously provided by Dr. R. H. Goodman (Oregon Health Science University, Portland, OR). pCMV-p300 was obtained from Dr. S. Grossman (Dana Farber Cancer Research Institute, Boston, MA). pCI-PCAF encoding the human PCAF and PCAF antibody were kind gifts of Dr. Y. Nakatani (National Institutes of Health, Bethesda, MD).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Activation of MGMT by TSA-- To investigate whether chromatin remodeling via histone acetylation plays a regulatory role in MGMT expression, we examined the effect of TSA, a specific histone deacetylase inhibitor, on MGMT expression. Northern blot analysis showed that the level of MGMT mRNA, when normalized with respect to the level of 18 S rRNA, was approximately 3-fold higher at 24 h after treatment with 100 ng/ml TSA (Fig. 1A). Concomitantly, we observed approximately a 3.5-fold increase in the MGMT protein level by Western blot analysis (Fig. 1B). Time course studies on the MGMT protein level showed that the increased level of the MGMT protein could be detected after 16 h of TSA treatment, with the protein level reaching the maximum by 24 h (Fig. 1C). These results raised the possibility that inhibition of histone deacetylation was responsible for activating the MGMT gene. Because TSA was shown earlier to arrest cell cycle progression in some cell lines in the G1 or G2/M phase (33), we used fluorescence-activated cell sorting to investigate the effects of various amounts of TSA on cell cycle progression of MIA PaCa-2 cells. TSA at 100 ng/ml had a negligible effect on cell cycle progression in this cell line (Table I). Consequently, we used 100 ng/ml TSA for MGMT activation in all subsequent studies.


View larger version (34K):
[in this window]
[in a new window]
  		Fig. 1.   TSA-mediated activation of MGMT mRNA and protein in MIA PaCa-2 cells. A, level of MGMT mRNA by Northern blot analysis at 24 h after treatment with indicated amounts of TSA. The level of 18 S rRNA was determined in the same blot to correct for gel loading variation. B, Western blot analysis of MGMT in extracts of cells treated with TSA as in A. C, time course of MGMT activation after TSA treatment (100 ng/ml). Other details are described under "Experimental Procedures." C, control.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Cell cycle analysis of MIA PaCa-2 cells treated with TSA
MIA PaCa-2 cells were treated with TSA (100 ng/ml) or ethanol vehicle (0.1%) for 24 h, and analyzed for cell cycle distribution (104 cells/sample) by fluorescence-activated cell sorting in a Becton-Dickinson FACScan.

Activation of the MGMT Promoter by TSA-- Because earlier studies indicated that the primary effect of inhibiting histone deacetylation is to modulate transcription of a subset of genes (23), we determined whether TSA-mediated activation of MGMT occurred at the promoter level. An MGMT promoter-luciferase reporter construct (p-954/+24ML), containing the MGMT promoter sequence from -954 to +24 base pairs (13), was used for transient expression of luciferase reporter in transfected MIA PaCa-2 cells as described under "Experimental Procedures." SV40 promoter-dependent luciferase expression plasmid was used as the control. TSA (100 ng/ml) activated MGMT promoter-driven luciferase expression by some 40-fold. Some promoter activation (~4-fold) could be detected with TSA concentration of as low as 20 ng/ml. We also observed a ~5-fold increase in luciferase activity driven by the SV40 promoter, consistent with an earlier observation (34). A time-course study on reporter expression with 100 ng/ml TSA showed that activation of luciferase could be detected after 4 h of TSA treatment, and the enzyme activity reached the maximum after approximately 24 h.

Two AP-1 Binding Elements Are Necessary for Promoter Activation by TSA-- To identify the factors that are responsible for TSA-induced activation of the MGMT promoter, we carried out promoter deletion and mutagenesis analysis. MIA PaCa-2 cells were transiently transfected with a series of 5' promoter deletion constructs, treated with TSA, and the luciferase activity then measured with cell-free extracts. A 10-fold activation of the promoter activity by TSA was observed with the minimal promoter reporter construct (p-72/+24ML), whereas the maximum induction (~ 45-fold) was observed with the (p-954/+24ML) promoter reporter (Table II). Interestingly, only a ~25-fold increase was observed after TSA treatment with the longer, p-3500/+24ML, reporter construct. This result suggests the presence of a negative regulatory element in the upstream (-3500 to -954 bp) region of the MGMT promoter. The presence of a similar negative regulatory element was also observed in TSA-mediated activation of p21/WAF1 promoter (35). Deletion of the promoter sequence from -954 to -575 base pairs decreased TSA-mediated induction by 2.5-fold. Further deletion of the sequence to position -72 decreased TSA-mediated induction by 4-fold. In any case, we conclude from these data that the cis elements required for promoter activation by TSA are present within the -72 bp region and between -575 and -954 bp upstream of the transcription start site.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Deletion and mutational analysis of MGMT promoter in reporter assay for TSA response
MIA PaCa-2 cells were transfected with 15 µg of indicated plasmids and luciferase reporter activity was quantitated. -Fold induction of luciferase activity under the control of wild type MGMT promoter segments and of promoters containing single and double AP-1 mutations is shown.

Examination of the sequence within the -72 bp region revealed the presence of three Sp1-binding sites. Earlier in vivo footprinting studies showed DNA protein interaction at six Sp1 sites, including these three sites, in an MGMT-expressing cell line (18). Examination of the sequence between -954 and -575 bp revealed several transcription factor-binding sites (12), including two AP-1 sites and two GREs. The AP-1 sites and GREs were previously shown to be involved in activation of MGMT with phorbol ester and dexamethasone, respectively (13, 14). To determine which, if any, of these two AP-1-binding elements are required for TSA-mediated induction, cells were transfected with MGMT promoter-luciferase constructs in which both AP-1 sites were mutated, individually or simultaneously. Mutation of both AP-1 sites reduced the basal activity by 2-3-fold (data not shown). However, as shown in Table II, mutation of either AP-1 site reduced TSA-mediated activation from ~ 45-fold to ~ 9-fold. Mutation of both AP-1 sites caused no additional reduction of activation over that observed with single mutations. Deletion of the two GREs had no effect on TSA-mediated induction (data not shown). These data indicate that two AP-1 sites but not GREs are involved in MGMT promoter activation by TSA.

Inhibition of MGMT Promoter Activity by Adenovirus E1A and Requirement of Transcriptional Coactivator CBP/p300 in Basal MGMT Expression-- Because two AP-1-binding elements were found to be necessary for TSA-mediated activation, we considered the possibility that TSA-induced MGMT promoter activation resulted from interaction between the AP-1 transcription factor and histone acetyltransferase or deacetylase. In view of the earlier observation that CBP/p300 interacts with AP-1 proteins in vivo (27, 28) and possesses HAT activity (30), it appeared that CBP/p300 could act as a coactivator in MGMT promoter expression. We tested this by investigating the effect of the adenovirus E1A protein, which binds to the CH3 domain of CBP/p300 and abolishes its coactivator function (28, 36). Cotransfection of cells with a fixed amount of MGMT promoter-luciferase reporter plasmid and varying amounts of an E1A expression plasmid showed strong inhibition of luciferase expression in an E1A dose-dependent manner, and a maximum of 10-fold reduction was observed with 5 µg of E1A plasmid (Fig. 2A). Because E1A binds to multiple regulatory proteins, including the retinoblastoma gene product Rb (37), the possibility remained that E1A inhibited MGMT promoter activity by binding to other factors needed for MGMT activation, in addition to CBP/p300. To test this, we cotransfected cells with an MGMT promoter-reporter construct and an expression vector for amino-terminal deletion, Delta 2-36 E1A, which was shown to be defective in CBP/p300 binding but capable of binding to members of the Rb protein family (38). As shown in Fig. 2B, mutant Delta 2-36 E1A did not inhibit MGMT promoter-luciferase expression; rather, an increase in promoter activity was reproducibly observed. Taken together, these results suggest that transcriptional coactivator CBP/p300 is involved in MGMT promoter expression.


View larger version (24K):
[in this window]
[in a new window]
  		Fig. 2.   Inhibition of MGMT promoter activity by wild type adenovirus E1A but not E1A mutant lacking the CBP/p300-binding domain. A, MIA PaCa-2 cells were transiently cotransfected with 15 µg of MGMT promoter-luciferase plasmid (p-954/+24ML) and increasing amounts of expression plasmid encoding wild type (wt) E1A (pCMV-E1A) or empty expression vector (0). Luciferase activity was measured at 48 h after transfection and normalized for the amount of protein. Results represent the mean ± S.D. of six independent experiments. B, comparison of inhibition of luciferase expression by wild-type and Delta 2-36 mutant E1A. The amount of E1A plasmid used for transfection is indicated.

E1A Inhibits TSA-mediated MGMT Activation-- Recent reports indicate that E1A directly represses the histone acetyltransferase activity of both CBP/p300 and its associated factor PCAF in vitro and during p300-dependent transcription in vivo (39). We therefore asked whether the HAT activity associated with CBP/p300 or the CBP/p300-PCAF complex was responsible for TSA-mediated activation of the MGMT promoter. We cotransfected cells with 15 µg of the (p-954/+24ML) MGMT promoter construct and different amounts of the E1A expression vector. Twenty-four h after transfection, the cells were treated with TSA or ethanol for another 24 h. As shown in Fig. 3, E1A inhibited TSA-mediated induction of the MGMT promoter in a dose-dependent fashion. These data provide the first in vivo evidence for TSA-mediated activation of a natural promoter in a reporter plasmid, which could be inhibited by E1A.


View larger version (12K):
[in this window]
[in a new window]
  		Fig. 3.   Inhibition of TSA-activable promoter function by E1A. MIA PaCa-2 cells were cotransfected with 15 µg of MGMT promoter-luciferase plasmid (p-954/+24ML) and 0.1 to 5 µg of E1A expression plasmid or the empty pcDNA3 vector (0). -Fold induction was calculated as the ratio of luciferase activity from TSA-treated versus ethanol-treated cells.

Overexpression of p300 and CBP Enhanced MGMT Promoter Activity and Potentiated Transactivation with TSA-- To provide direct evidence for involvement of CBP/p300 in MGMT promoter activation, we examined the effect of overexpression of p300 and/or CBP on reporter activity. Ectopic expression of full-length human p300 increased MGMT promoter-driven luciferase activity by 5-fold (Fig. 4A). Similarly, overexpression of full-length mouse CBP enhanced MGMT promoter-driven luciferase activity by 2-fold (Fig. 4B). Furthermore, ectopic expression of p300 or CBP had a synergistic effect with TSA (Fig. 4, A and B).


View larger version (25K):
[in this window]
[in a new window]
  		Fig. 4.   Activation of the MGMT promoter by ectopic expression of p300 and CBP. Cells were cotransfected with 15 µg of MGMT promoter-luciferase plasmid (p-954/+24ML) and 0-5 µg of expression plasmid for human p300 in A or mouse CBP in B. C, reversal of E1A-mediated inhibition of MGMT promoter activity by p300. Cells were cotransfected with 15 µg of MGMT promoter-luciferase plasmid, 0.1 µg of E1A expression plasmid, and 5 µg of human p300 expression plasmid or empty pcDNA3 vector. Luciferase activity was assayed at 48 h after transfection and normalized for the amount of protein in the extracts.

Co-expression of CBP and its associated factor PCAF, which also possesses HAT activity, did not show a significant additional synergistic effect with TSA (data not shown). To show more directly that the E1A-mediated inhibition of MGMT promoter activity was due to squelching of CBP/p300, we asked whether overexpression of CBP/p300 could restore the promoter activity in the presence of E1A. Ectopic expression of p300 completely reversed the inhibition of MGMT promoter activity with E1A, suggesting that this inhibition was indeed due to titration of a limiting amount of endogenous CBP/p300 (Fig. 4C). These data provide further support for involvement of CBP/p300 in MGMT promoter activation.

Inhibition of the Minimal MGMT Promoter by E1A-- TSA-mediated enhancement of MGMT minimal promoter-driven luciferase expression (Table II) raised the possibility that CBP/p300 is involved in the function of the MGMT minimal promoter as well. We tested this by cotransfecting cells with a fixed amount of (p-72/+24ML) promoter reporter plasmid and increasing amount of wild type or mutant E1A expression plasmid. Fig. 5A shows that wild type E1A strongly inhibited MGMT promoter activity, while mutant E1A did not. In fact, the mutant protein had a stimulatory effect on the promoter activity as was also observed with the longer promoter (p-954/+24ML) (Fig. 2B). Moreover, ectopic expression of p300 enhanced the minimal promoter-dependent luciferase activity (Fig. 5B). The -72 bp minimal promoter region is highly GC-rich, and three Sp1-binding sites in this segment were previously shown to be functional in vivo (18). Thus, it appears that the transcriptional co-activator CBP/p300 is also required for the minimal basal promoter activity of the MGMT gene, which acts presumably by recruiting Sp1 transcription factors, or by directly interacting with the basal transcription machinery.


View larger version (24K):
[in this window]
[in a new window]
  		Fig. 5.   Inhibition of the minimal MGMT promoter by E1A. A, cells were cotransfected with 15 µg MGMT promoter-luciferase plasmid (p-72/+24ML) and 0.4 or 1 µg of expression plasmid encoding wild-type (wt) E1A or mutant Delta 2-36 E1A or the empty expression vector. Luciferase activity was determined as in Fig. 4. B, activation of minimal MGMT promoter by p300. Cells were cotransfected with 15 µg of MGMT promoter-luciferase plasmid (p-72/+24ML) and 5 µg of p300 expression plasmid, or empty pcDNA3 vector. Luciferase activity was determined at 48 h after transfection.

TSA Caused Accumulation of Acetylated Histones in MIA PaCa-2 Cells-- TSA was shown to cause accumulation of acetylated histone species in various mammalian cell lines, which could be separated by AUT gel electrophoresis (22). We investigated the effect of TSA (100 ng/ml) on histone acetylation in MIA PaCa-2 cells by analyzing histones from TSA-treated or untreated cells. Fig. 6A shows that higher levels of tri- and tetra-acetylated forms of H4 and H2B histones were present in the TSA-treated cells relative to the control. Hyperacetylated histone H4 plays a critical role in enhancing the binding of transcription factors to nucleosomal DNA in vitro (40). Therefore, to determine the abundance of hyperacetylated histone H4 after TSA treatment, immunoblot analysis was carried out using anti-acetylated histone H4 antibody which recognizes tri- and tetra-acetylated isoform of histone H4. As shown in Fig. 6B, TSA treatment caused a significant increase in the level of hyperacetylated histone H4 in these cells.


View larger version (25K):
[in this window]
[in a new window]
  		Fig. 6.   Effects of TSA on histone acetylation. Histones were acid-extracted from nuclei following their isolation from cells after treatment with 100 ng/ml TSA or ethanol for 9 h, and analyzed as described under "Experimental Procedures." A, Coomassie Blue-stained gel showing separated histones and isoforms of acetylated H2B and H4 histones separated by AUT gel electrophoresis. B, Western blot analysis of AcH4 with anti-AcH4 antibody after SDS-PAGE. Cross-reacted acetylated H2B (uppermost band) was also detected.

Effect of TSA Treatment on the Abundance of Hyperacetylated Histone H4 Bound to the MGMT Promoter in Vivo-- The observation that TSA modulates expression of only 2% of cellular genes implies that histone acetylation is targeted to specific genes or chromosomal domains (23), and that such targeting is achieved by recruitment of HAT to the signal-responsive promoters. In order to show that TSA specifically increased acetylation of histones bound to the MGMT promoter in vivo, we utilized chromatin immunoprecipitation (CHIP) assay as outlined in Fig. 7A. MIA PaCa-2 cells were treated with TSA for 9 h, and then the cells on the dish were treated with formaldehyde and the fragmented chromatin was isolated and immunoprecipitated with anti-acetylated histone H4 antibody. PCR amplification of an MGMT promoter sequence was carried out with DNA extracted from the immunocomplex. Fig. 7B shows that the MGMT promoter sequence was significantly enriched (3-4-fold) in the immunocomplex containing hyperacetylated H4 histone from TSA-treated cells (lane 3) compared with that from the control cells (lane 6). Appropriate controls used in this experiment provided further support for this observation. Thus, little or no MGMT promoter sequence was detected by the PCR assay in the absence of anti-acetylated histone H4 antibody (lane 7). Similarly, enrichment of the MGMT promoter sequence was not observed when a nonspecific antibody was used (lane 4). Furthermore, as expected, no PCR product was observed when the formaldehyde cross-linking step was omitted (lane 5). In order to establish that TSA treatment enhanced the level of hyperacetylated histones selectively bound to the MGMT promoter rather than to the MGMT gene as a whole, we used the PCR assay to determine the relative amounts of the MGMT promoter sequence and exon 2 sequence in the hyperacetylated histone H4 immunocomplex. No difference was found in the abundance of hyperacetylated histone H4 in the MGMT exon 2 region before and after TSA treatment (lanes 8 and 9). We extended this study to analyze the acetylation status of nucleosomes formed at the MGMT promoter sequence of the transfected plasmid molecules. Chromatin immunoprecipitation was carried out using MIA PaCa-2 cells transfected with MGMT promoter-reporter (p-954/+24ML). The MGMT promoter was again found to be selectively associated with acetylated histone H4 (Fig. 7C, lane 4), and TSA treatment caused a significant increase in the amount of acetylated histone H4 associated with this promoter (Fig. 7C, lane 6). No significant change in the level of acetylated histone H4 in the non-coding region of MGMT promoter-reporter was observed as a result of TSA treatment (lanes 13 and 14). These results indicate that the transfected MGMT promoter was preferentially associated with hyperacetylated histone H4 in the presence of TSA.


View larger version (35K):
[in this window]
[in a new window]
  		Fig. 7.   A, an outline of the CHIP assay as described under "Experimental Procedures." B, CHIP assay of AcH4 bound to the endogenous MGMT promoter. Lanes 1 and 2, control and TSA-treated total chromatin; lanes 3, 4, and 7, MGMT promoter sequence from TSA-treated cells, cross-linked and immunoprecipitated with indicated antibodies; lane 5, without cross-linking; lane 6, immunoprecipitated MGMT promoter from control; lanes 8 and 9, MGMT exon 2 region with anti-AcH4 antibody from TSA-treated and control cell extracts. C, CHIP assay of AcH4 bound to transfected plasmid (p-954/+24ML). Lanes 1 and 2, TSA-treated or ethanol-treated total chromatin, respectively; lanes 3 and 5, MGMT promoter without antibody from control and TSA-treated cell extract, respectively; lanes 4 and 6, immunoprecipitated MGMT promoter with anti-AcH4 antibody from control and TSA-treated cell extract, respectively; lanes 7-12, CHIP assay of AcH4 bound to two AP-1 mutated transfected plasmids; lanes 13 and 14, non-coding region of pGL2 basic vector with anti-AcH4 antibody from TSA-treated and control cell extracts, respectively. D, CHIP assay for in vivo association of p300 with MGMT promoter in (p-954/+24ML) plasmid. MGMT promoter immunoprecipitated with anti-p300 antisera (lane 4), nonspecific serum (lane 3), no antiserum (lane 2), and buffer alone (lane 1).

To provide evidence that TSA-mediated activation of MGMT promoter involved the AP-1 sites, we carried out CHIP assay with MIA PaCa-2 cells transfected with MGMT promoter-reporter (p-954/+24ML) containing mutated AP-1 sites. As shown in Fig. 7C, TSA treatment did not increase significantly the level of acetylated histone H4 when the two AP-1 elements were mutated (lane 10). We, therefore, propose that AP-1 binding elements are essential for TSA-induced association of acetylated histones with the MGMT promoter.

Association of p300 with MGMT Promoter-- The results of the CHIP assay are consistent with the scenario that TSA increased the level of hyperacetylated histones bound to the MGMT promoter in both endogenous and episomal states, and that such acetylation was mediated by the HAT activity of CBP/p300. It was thus important to establish that CBP/p300 is indeed associated with the MGMT promoter sequence in vivo. We transfected MIA PaCa-2 cells with the (p-954/+24ML) reporter plasmid. After formaldehyde cross-linking followed by chromatin isolation, we isolated immunocomplex by adding anti-human p300 antisera. After reversal of cross-links and DNA extraction from the immunocomplex, a 460-bp segment of the MGMT promoter was amplified by PCR. Fig. 7D shows that the MGMT promoter sequence was selectively enriched by treatment with anti-p300 antibody and not with nonspecific sera. These results suggest that p300 is normally associated with the MGMT promoter, at least in the episomal state.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

This report provides the first evidence that histone acetylation plays a role in MGMT expression, because both endogenous MGMT gene expression and MGMT promoter-driven reporter expression were enhanced by TSA, a histone deacetylase inhibitor. However, it was somewhat unexpected that TSA activated the MGMT promoter in the episomal state to a much greater extent than the promoter of the chromosomal MGMT gene. It was previously shown that transfected plasmids interact with histones to form nucleosome-like structures so that inhibiting histone deacetylase activity could activate transcription from such plasmids (35, 41). A possible explanation for large activation of the episomal MGMT promoter by HDAC inhibitor is that even though the nucleosome structure of transfected genes may not be normal (42), histone association is still required for transcription from their promoters. Furthermore, acetylation of histones could result in a more open chromatin structure in the episomal gene promoters than in the chromosomal promoters. The large magnitude of activation due to the inhibition of histone acetylation may also reflect a gene dosage effect, due to the large copy number of episomal promoters compared with two copies in the chromosomal DNA. It is also possible that many transfected plasmid molecules form complexes with histones in a closed form not suitable for transcription until the histones are acetylated.

Our earlier studies showed that two AP-1 sites in the MGMT promoter are involved in its activation by phorbol esters (14). The present study showing that these AP-1 sites are also involved in TSA-mediated activation of the MGMT promoter suggests that the cofactors recruited at these sites possess HAT activity. This would result in targeted acetylation of histones, leading to loosening of the nucleosome structure in the promoter region which, in turn would facilitate binding of AP-1 and Sp1 transcription factors. This possibility is supported by the observation that ectopic expression of the transcriptional coactivator CBP/p300 enhanced MGMT promoter activity (Fig. 4, A and B). CBP/p300 was shown to bind c-Jun, c-Fos, and several other transcription factors (27, 29). We propose a simple scenario in which AP-1 recruits CBP/p300 whose HAT activity causes histone acetylation in the promoter leading to a local disruption of nucleosomes and facilitating binding of the general transcription machinery. Under normal conditions, the HAT function would be partially antagonized by an HDAC; TSA treatment would relieve this antagonism and enhance the levels of hyperacetylated histones. Further evidence for the role of HAT activity of CBP/p300 was provided by the observation that overexpression of the adenovirus E1A protein abolished TSA-mediated promoter activation nearly completely (Fig. 3). This result is consistent with the recent finding of Chakrabarti et al. (39) that E1A is a potent inhibitor of the HAT activity of CBP/p300, as well as that of free PCAF and PCAF bound to CBP/p300. E1A binds to the same CH3 domain of CBP/p300 at which other key regulatory proteins interact, and directly inhibits its HAT activity (39).

Additional confirmation of the role of CBP/p300 in MGMT gene regulation was provided by our result that the MGMT basal promoter is activated by episomal expression of CBP/p300 in a dose-dependent manner (Fig. 4A). Furthermore, the failure of the NH2-terminally truncated protein Delta 2-36 E1A to inhibit the basal promoter activity (Fig. 2B) suggests that E1A inhibition is exclusively dependent on its binding to CBP/p300. Surprisingly, mutant Delta 2-36 E1A also increased basal transcription of the MGMT promoter. Similar results were previously described for p21 and p15 promoters (43). We have no obvious explanation for this unexpected finding.

Apart from its HAT activity, CBP/p300 provides a link between specific transcription factors and the general transcription machinery via binding to TFIIB and TATA-binding protein TBP (44). Thus, E1A could inhibit basal MGMT promoter activity by titrating the limiting amount of CBP/p300 present in the cell, and thereby prevents its interaction with other transcription factors or a component of the transcription machinery. Consistent with this hypothesis, overexpression of CBP/p300 eliminates promoter repression by E1A (Fig. 4C). Thus, E1A may inhibit CBP/p300, and thereby MGMT promoter, via one or both of two possible mechanisms, i.e. either by inhibiting intrinsic HAT activity of CBP/p300, and/or by inhibiting interaction of CBP/p300 with transcription factors (AP-1 and Sp1) or the basal transcription machinery. Western blot analysis showed no change in the protein levels of c-Jun, CBP, and PCAF as a function of time after TSA treatment (data not shown). We have thus eliminated an alternative possibility that TSA activation of MGMT could be an indirect effect of enhanced levels of c-Jun or CBP or PCAF.

Using CHIP assay, we have provided direct evidence that TSA increased the amount of hyperacetylated histone selectively bound to the MGMT promoter and not to the coding region. Furthermore, using mutant AP-1 containing reporter plasmid, we showed that AP-1 sites were involved in TSA-mediated activation. Such activation of genes could involve distinct trans-acting factors. For example, Sp1 is required in the case of P21/WAF1, C/EBP, and Stat 5 in the case of beta -casein and NF-Y in the case of MDR1 promoter (35, 41, 45). We have shown in this report that TSA activation could also involve the AP-1 protein.

In summary, our studies support the model that transcriptional coactivator CBP/p300 is required for MGMT promoter function and that their recruitment leads to remodeling of the chromatin via histone acetylation, a prerequisite for MGMT promoter function. The mechanism of transcriptional inactivation of the MGMT gene in Mex- cells is not completely understood. It was suggested that altered chromatin organization, nucleosome positioning and reduced accessibility to DNA-interactive protein are associated with the Mex- phenotype (18). Quantitation of the level of histone acetylation associated with the MGMT promoter in Mex- cells may help sort out these possibilities.

    ACKNOWLEDGEMENTS

We thank Drs. P. K. Roychoudhury, R. H. Goodman, S. Grossman, and Y. Nakatani for providing various plasmids and antibodies. We are grateful to Dr. M. Mohiuddin and D. M. Kokkinakis for advice in culturing the MIA PaCa-2 cells. We acknowledge the help of Drs. T. Biswas, T. K. Hazra, and I. Boldogh in this study, and we thank Wanda Smith for secretarial assistance and Dr. David Konkel for critically reading the manuscript.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant R01 ES 07572.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Sealy Center for Molecular Science, University of Texas Medical Branch, 6.136 Medical Research Bldg., Rt. 1079, Galveston, TX 77555. Tel.: 409-772-1780; Fax: 409-747-8608; E-mail: samitra@utmb.edu.

Published, JBC Papers in Press, August 14, 2000, DOI 10.1074/jbc.M005447200

    ABBREVIATIONS

The abbreviations used are: BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; AcH4, acetylated histone H4; AUT, acid-urea-Triton; bp, base pair(s); CBP, cAMP response element-binding protein-binding protein; CHIP, chromatin immunoprecipitation; HAT, histone acetyltransferase; HDAC, histone deacetylase; MGMT, O6 -methylguanine-DNA methyltransferase; ML, MGMT-luciferase; PCAF, p300/CBP-associated factor; TSA, trichostatin A; GRE, glucocorticoid-responsive element; PAGE, polyacrylamide gel electrophoresis.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Ludlum, D. B. (1990) Mutat. Res. 233, 117-126
2. Mitra, S., and Kaina, B. (1993) Prog. Nucleic Acids Res. Mol. Biol. 44, 109-142
3. Pegg, A. E., and Byers, T. L. (1992) FASEB J. 6, 2302-2310
4. Foote, R. S., Mitra, S., and Pal, B. C. (1980) Biochem. Biophys. Res. Commun. 97, 654-659
5. Citron, M. R., Decker, S., Chen, S., Schneider, S., Graver, M., Kleynerman, L., Khan, L. B., White, A., Schoenhaus, M., and Yarosh, D. (1991) Cancer Res. 51, 4131-4134
6. Washington, W. J., Foote, R. S., Dunn, W. C., Generoso, W. M., and Mitra, S. (1989) Mech. Ageing. Dev 48, 43-52
7. Day, R. S., III, Ziolkowski, C. H. J., Seudiero, D. A., Meyer, S. A., Lubiniecki, A. S., Giardi, A. J., Galloway, S. M., and Bynum, G. D. (1980) Nature 288, 724-727
8. Silber, J. R., Blank, A. M., Bobola, S., Mueller, D. A., Kolstoe, D. D., Ojemann, G. A., and Berger, M. S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6941-6946
9. Kokkinakis, D. M., Ahmed, M. M., Delgado, R., Fruitwala, M. M., Mohiuddin, M., and Albores-Saavedra, J. (1997) Cancer Res. 57, 5360-5368
10. Tano, K., Shiota, S., Collier, J., Foote, R. S., and Mitra, S. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 686-690
11. Nakatsu, Y., Hattori, K., Hayakawa, H., Shimizu, K., and Sekiguchi, M. (1993) Mutant. Res. 293, 119-132
12. Harris, L. C., Potter, P. M., Tano, K., Shiota, S., Mitra, S., and Brent, T. P. (1991) Nucleic Acids Res. 19, 6163-6167
13. Biswas, T., Ramana, C. V., Srinivasan, G., Boldogh, I., Hazra, T. K., Chen, Z., Tano, K., Thompson, E. B., and Mitra, S. (1999) Oncogene 18, 525-532
14. Boldogh, I., Ramana, C. V., Chen, Z., Biswas, T., Hazra, T. K., Grosch, S., Grombacher, T., Mitra, S., and Kaina, B. (1998) Cancer Res. 58, 3950-3956
15. von Wronski, M. A., Harris, L. C., Tano, K., Mitra, S., Bigner, D. D., and Brent, T. P. (1992) Oncol. Res. 4, 167-174
16. Harris, L. C., Potter, P. M., Remack, S. O., and Brent, T. P. (1992) Cancer Res. 52, 6404-6406
17. Qian, C. X, and Brent, T. P. (1997) Cancer Res. 57, 3672-3677
18. Costello, J. F., Futscher, B. W., Kroes, R. A., and Pieper, R. O. (1994) Mol. Cell. Biol. 14, 6515-6521
19. Grunstein, M. (1997) Nature 389, 349-352
20. Pazin, J. M., and Kadonaga, J. T. (1997) Cell 89, 325-326
21. Braunstein, M., Rose, A. B., Holmes, S. G., Allis, C. D., and Broach, J. R. (1993) Genes Dev. 7, 592-604
22. Yoshida, M., Kijima, M., Akita, M., and Beppu, T. (1990) J. Biol. Chem. 265, 17174-17179
23. Van lint, C., Emiliani, S., and Verdin, E. (1996) Gene Exp. 5, 245-253
24. Mizzen, C. A., and Allis, C. D. (1998) Cell. Mol. Life. Sci. 54, 6-20
25. Eckner, R., Ewen, M. E., Newsome, D., Gerds, M., Decaprio, J. A., Bentky-Lowrence, J., and Livingston, D. M. (1994) Genes Dev. 8, 869-884
26. Lundblad, J. R., Kwok, R. P., Laurance, M. E., Harter, M. L., and Goodman, R. H. (1995) Nature 374, 85-86
27. Lee, J. S., See, R. H., Deng, T., and Shi, Y. (1996) Mol. Cell. Biol. 16, 4312-4326
28. Bannister, A. J., and Kouzarides, T. (1995) EMBO J. 14, 4758-4762
29. Janknecht, R., and Hunter, T. (1996) Nature 383, 22-23
30. Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., and Nakatani, Y. (1996) Cell 87, 953-959
31. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , 2nd Ed. , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
32. Cousens, L. S., Gallwitz, D., and Alberts, B. M. (1979) J. Biol. Chem. 254, 1716-1723
33. Hoshikawa, Y., Kwon, H. J., Yoshida, M., Horinouchi, S., and Beppu, T. (1994) Exp. Cell. Res. 214, 189-197
34. Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., and Horinouchi, S. (1998) Exp. Cell. Res. 241, 126-133
35. Sowa, Y., Orita, T., Minamikawa, S., Nakanu, K., Mizuno, T., Nomura, H., and Sakai, T. (1997) Biochem. Biophys. Res. Commun. 241, 142-150
36. Arany, Z., Newsome, D., Oldread, E., Livingston, D. M., and Eckner, R. (1995) Nature 374, 81-84
37. Whyte, P., Buchkovich, K., Horowitz, J. M., Friend, S. H., Raybuck, M., Weinberg, R. A., and Harlow, E. (1988) Nature 334, 124-129
38. Stein, R. W., Corrigan, M., Yaciuk, P., Whelan, J., and Moran, E. (1990) J. Virol. 64, 4421-4427
39. Chakravarti, D., Ogryzko, V., Kao, H.-Y., Nash, A., Chen, H., Nakatani, Y., and Evans, R. M. (1999) Cell 96, 393-403
40. Dadey, M. V., Grant, P. A., Hebbes, T. R., Robinson, C. C., Allis, C. D., and Workman, J. L. (1996) EMBO J. 15, 2508-2518
41. Jin, S., and Scotto, K. W. (1998) Mol. Cell. Biol. 18, 4377-4384
42. Jeong, S., and Stein, A. (1994) Nucleic Acids Res. 22, 370-375
43. Owen, G. I., Richer, J. K., Tung, L., Takinoto, G., and Hortwitz, K. B. (1998) J. Biol. Chem. 273, 10696-10701
44. Kim, T. K., Kim, T. H., and Maniatis, T. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 12191-12196
45. Myes, C. A., Schmidnauser, C., Mellintin-Micnelotti, J., Fragoso, G., Roskelley, C. D., Casperson, G., Mossi, R., Pujuguet, P., Hager, G., and Bisell, M. J. (1998) Mol. Cell. Biol. 18, 2184-2195

Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
M. M. Alonso, C. Gomez-Manzano, B. N. Bekele, W.K. A. Yung, and J. Fueyo
Adenovirus-Based Strategies Overcome Temozolomide Resistance by Silencing the O6-Methylguanine-DNA Methyltransferase Promoter
Cancer Res., December 15, 2007; 67(24): 11499 - 11504.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Fontijn, A. D. Adema, K. K. Bhakat, H. M. Pinedo, G. J. Peters, and E. Boven
O6-Methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells
Mol. Cancer Ther., October 1, 2007; 6(10): 2807 - 2815.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
F. Alimirah, J. Chen, F. J. Davis, and D. Choubey
IFI16 in Human Prostate Cancer
Mol. Cancer Res., March 1, 2007; 5(3): 251 - 259.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. K. Bhakat and S. Mitra
CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration
Carcinogenesis, August 1, 2003; 24(8): 1337 - 1345.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
X. Li, J. Wong, S. Y. Tsai, M.-J. Tsai, and B. W. O'Malley
Progesterone and Glucocorticoid Receptors Recruit Distinct Coactivator Complexes and Promote Distinct Patterns of Local Chromatin Modification
Mol. Cell. Biol., June 1, 2003; 23(11): 3763 - 3773.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. P. Margison, A. C. Povey, B. Kaina, and M. F. Santibanez Koref
Variability and regulation of O6-alkylguanine-DNA alkyltransferase
Carcinogenesis, April 1, 2003; 24(4): 625 - 635.
[Abstract] [Full Text] [PDF]

Home page